Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med's Parent, C.K. Hutchison, Sells $288 Million of Chi-Med Stock

publication date: Jul 1, 2019

Hutchison China MediTech (Chi-Med) reported its parent company, a division of Hong Kong conglomerate CK Hutchison, sold $288 million of its Chi-Med stake. The secondary offering placed 12 million ADSs at $24 each, upsized from 8.5 million ADSs originally planned. The placement will reduce Hutchison Healthcare Holdings' share of Chi-Med to 51.2%, which will drop further to 49.8% if the underwriters choose to exercise an option for an additional 1.8 million ADSs. All of the funds will belong to the parent company. Chi-Med currently has a market capitalization of $3 billion. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.